Category:

Teresa Rubio, PharmD of the FDA Office on Health and Constituents Affairs describes the types of adverse drug events that pharmacists should report to MedWatch.

Katie Greenlee, PharmD, BCPS-AQ Cardiology, of the Cleveland Clinic discusses how NOAC (novel oral anticoagulants) dosing for obese patients differs from NOAC dosing for non-obese patients.

Marc O'Connor, chief operating officer of Curant Health, discusses methods Curant uses to maintain adherence to specialty drug regimens.

Jennifer L. Costello, PharmD, BCPS, BC-ADM, ambulatory care clinical pharmacist at Saint Barnabas Medical Center

• Episode 1 New Pharmacological Agents for Treatment of Obesity
• Episode 2 Mechanisms of Action for New Weight-Loss Agents
• Episode 3 Risk and Benefit Profiles of Weight-Loss Medications
• Episode 4 What Pharmacists Should Prepare Patients for When Taking Weight-Loss Medications
• Episode 5 Key Takeaways from Recent Landmark Studies of Weight-Loss Drugs
• Episode 6 Counseling Points for Pharmacists with Patients on Weight-Loss Medications

SPECIALTY PHARMACEUTICALS featured prominently in the FDA’s new drug approval and expanded indications list once again in 2015. Below is the first of a 2-part summary of specialty pharmacy–related FDA approvals and expanded indications that took place this year...Part 2, which will be featured in the next issue of Specialty Pharmacy Times, will include oncology drugs and late-breaking FDA actions...

Bleeding Disorders

• Ixinity (coagulation factor IX (recombinant), Emergent BioSolutions Inc)
• Nuwiq (coagulation factor VIII (recombinant), Octapharma)
• Coagadex (coagulation factor X (human), Bio Products Laboratory Ltd)
• Adynovate (antihemophilic factor [recombinant] pegylated, Baxalta Inc)

Inflammatory Conditions

• Cosentyx (secukinumab, Novartis Pharmaceutical Corp.)
• Humira (adalimumab, AbbVie)

Cystic Fibrosis

• Kalydeco (ivacaftor, Vertex Pharmaceuticals)
• Orkambi (lumacaftor/ivacaftor, Vertex Pharmaceuticals )

HIV

• Evotaz (atazanvir/cobicistat, Bristol-Myers Squibb Co)
• Prezcobix (darunavir/cobicistat, Janssen Therapeutics)
• Genvoya (cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide, Gilead Sciences, Inc)

Hepatitis C

• Technivie (ombitasvir/paritaprevir/ritonavir, AbbVie Inc)
• Daklinza (daclatasvir, Bristol-Myers Squibb)
• Harvoni (ledipasvir/sofosbuvir, Gilead Sciences, Inc.)

• Glatopa (glatiramer acetate injection, Sandoz, Inc.)
• Betaconnect (Bayer HealthCare’s electronic auto injector - Betaseron (interferon beta-1b)

Specialty Ophthalmics

• Lucentis (ranibizumab, Genentech)
• Eylea (aflibercept, Regeneron Pharm)

Hypercholesterolemia

• Praluent (alirocumab, Sanofi-Aventis)
• Repatha (evolocumab, Amgen Inc)

Miscellaneous Specialty Approvals

• Natpara (parathyroid hormone, NPS Pharmaceuticals, Inc)
• Cresemba (isavuconazonium sulfate, Astellas Pharma US, Inc)
• Cholbam (cholic acid, Asklepion Pharmaceuticals LLC)
• Jadenu (deferasirox, Novartis Pharmaceuticals)
• Anthrasil (anthrax immune globulin intravenous [Human], Cangene Corp)
• Rapamune (sirolimus, Wyeth Pharmaceuticals)
• Promacta (eltrombopag, GlaxoSmithKline and Novartis Pharmaceuticals)
• Envarsus XR (tacrolimus extended-release tablets, Veloxis Pharmaceuticals A/S)
• Dysport (abobotulinumtoxinA, Medicis and Ipsen)
• Keveyis (dichlorphenamide, Taro Pharmaceutical Industries Ltd)
• Procysbi (cysteamine bitartrate, Raptor Pharmaceutical)
• Xuriden (uridine triacetate, Wellstat Therapeutics Corporation)

Andi Lane Clark, PharmD, Director of Clinical Field Services at Rite Aid, forecasts several different innovative solutions that are poised to drive better medication adherence over the next 2-3 years.

Andi Lane Clark, PharmD, Director of Clinical Field Services at Rite Aid, discusses how proper medication adherence habits allow patients to better manage their chronic conditions.

Pharmacists should learn how to properly diagnose foreign-acquired diseases in order to optimize outcomes for infected patients...these diseases are rarely seen in US emergency departments, health-system pharmacists might nevertheless encounter them during their careers...It’s important to recognize these diseases and know what you need to help them, [but] you don’t need to be an expert...Pharmacists can also play a role in preventing these diseases by reminding patients that they must follow their entire prescribed regimen when taking drugs prior to travel...The following are some exotic diseases primarily coming from Southeast Asia that pharmacists should know:

• Malaria
• Dengue Fever
• Typhoid Fever

Chronic obstructive pulmonary disease patients could spend less time in the hospital if their doctors utilize a checklist of steps called order sets, according to findings published in the Canadian Respiratory Journal…Researchers from St. Michael’s Hospital in Toronto…examined the effects of order sets on hospital stay…Using order sets to manage worsening COPD can lead to better medical care and better results for patients…By providing doctors with the best, evidence based information at the point in time when they are deciding on medications and tests for their patients, we can improve doctors' adherence to best practices…Our next step is to advocate for these order sets to be implemented across the healthcare system, to ensure that these patients receive best evidence based and standardized care..

Pharmacists should take some time to counsel patients on the pros and cons of each antidepressant to help them select the best regimen…Decision aids produced by the Mayo Clinic inform health care providers of the nuances between medications and how each drug may affect a patient…Here are 5 key facts about these antidepressants that warrant clarification for patients:

1. Weight Changes
2. Sexual Issues
3. Insomnia or Sleepiness
4. Cost
5. Stopping Treatment